Table 1.

Clinical Features of Patients Who Developed Symptomatic SARS-CoV-2 Infection

Clinical features	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Sex	Female	Female	Female	Male	Female
Age, y	45	41	60	55	58
Liver disease	AIH	AIH	AIH	AIH	PBC
Liver stiffness, kPa	5.8	4.4	5.2	40.0	4.3
CAP, dB/m	161	165	274	185	159
Cirrhosis	No	No	No	Yes	No
Arterial hypertension	No	No	No	No	No
Diabetes mellitus	No	Yes	No	No	No
Obesity	No	No	Yes	No	No
Rheumatologic disease	No	No	No	No	Yes
Prednisone, mg/d	8.75	6.25	2.5	50	5a
Azathioprine, mg/d	0	125	75	0	100a
Before SARS-CoV-2b
Hospital outpatient visit	No	No	Yes	Yes	No
Hospitalization	No	No	No	No	No
Workingc	Yes	Yes	No	Yes	No
SARS-CoV-2 management
Hospitalization	Yes	No	No	Yes	No
Hydroxychloroquine	Yes	Yes	Yes	Yes	Yes
Lopinavir/ritonavir	Yes	No	No	Yes	No
Azithromycin	No	Yes	Yes	No	No
Outcome	Alive	Alive	Alive	Alive	Alive

NOTE. Each patient was assigned a number.

AIH, autoimmune hepatitis; CAP, controlled attenuation parameter; PBC, primary biliary cholangitis; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

^aImmunosuppressive therapy for undifferentiated connective tissue disease.

^bIn late February 2020.

^cPatients 1 and 2 had been working as a cashier (patient 1 at a restaurant and patient 2 at a grocery store). Patient 4 had been working from home.